NCT07431788 The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual Function
| NCT ID | NCT07431788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erkan Gol |
| Condition | Leiomyoma (Uterine Fibroids) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-03-02 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-03-02 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, single-center, randomized controlled trial aims to evaluate the effect of uterine manipulator use during total abdominal hysterectomy on postoperative female sexual function at 3 months, assessed by the Female Sexual Function Index (FSFI). Secondary outcomes include operative time, perioperative hemoglobin change, postoperative pain (VAS), hospital stay duration, and 30-day complications.
Eligibility Criteria
Inclusion Criteria: * Women aged ≥18 years * Planned total abdominal hysterectomy for benign indications * Sexually active within the last 4 weeks * Able to complete the Female Sexual Function Index (FSFI) questionnaire * Provided written informed consent Exclusion Criteria: * Gynecologic malignancy * Major additional pelvic reconstructive surgery * Severe psychiatric or neurologic disorder * Inability to complete follow-up assessments
Contact & Investigator
Erkan Göl, MD
PRINCIPAL INVESTIGATOR
University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
Frequently Asked Questions
Who can join the NCT07431788 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Leiomyoma (Uterine Fibroids). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07431788 currently recruiting?
Yes, NCT07431788 is actively recruiting participants. Contact the research team at drerkangol@gmail.com for enrollment information.
Where is the NCT07431788 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07431788 clinical trial?
NCT07431788 is sponsored by Erkan Gol. The principal investigator is Erkan Göl, MD at University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. The trial plans to enroll 60 participants.